
Expert Insight Into:
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer (Part 1 of Series)
Medical Writer: Nicole M. Avena, PhD
Expert Faculty: Corey J. Langer, MD, FACP
Medical Writer: Nicole M. Avena, PhD
Expert Faculty: Corey J. Langer, MD, FACP
Click here to view our current activities in Oncology.
EGFR gene mutations can produce hypersensitivity to EGFR tyrosine kinase inhibitors in patients with NSCLC, but studies investigating the clinical benefit of this approach in these patients have been lacking. Dr. Corey Langer comments on the findings from a prospective, large-scale study of erlotinib in NSCLC patients with EGFR mutations.

Corey J. Langer, MD, FACP
- Professor of Medicine
- Hematology-Oncology Division
- Department of Medicine
- University of Pennsylvania
- Philadelphia, Pennsylvania

Walter J. Curran, Jr., MD, is a consultant for Eli Lilly and Company, GlaxoSmithKline, and ImClone Systems; and has ownership interest in ITA Partners.
Jessica S. Donington, MD, has disclosed no significant relationships.
Roy S. Herbst, MD, PhD, has received grant/research support from Amgen Inc, AstraZeneca, Bristol-Myers Squibb, Genentech, Inc, Geron Corporation, Novartis Pharmaceuticals, Oncothyreon, OSI Pharmaceuticals, Inc., and sanofi-aventis; is an advisor for Amgen Inc, AstraZeneca, Bristol-Myers Squibb, and Eli Lilly and Company; and is a consultant for Amgen Inc, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc, and SynDevRx.
Corey J. Langer, MD, FACP, has received grant/research support from Bristol-Myers Squibb, Genentech, Inc, ImClone Systems, Lilly USA, LLC, OSI Pharmaceuticals, Inc. and Pfizer, Inc; is an advisor for Abbott Laboratories, Abraxis, Amgen Inc, AstraZeneca, Bayer/Onyx, Biodesix, Bristol-Myers Squibb, Caris Dx, Clarient, Inc, Genentech, Inc, ImClone Systems, Lilly USA, LLC, Morphotek, Novartis Pharmaceuticals, Pfizer, Inc, and sanofi-aventis; and is on the speakers bureau of Genentech, Inc, ImClone-BMS, Lilly USA, LLC, and OSI Pharmaceuticals Inc.
Vincent A. Miller, MD, is a consultant for ArQule, Inc, Boehringer Ingelheim Pharmaceuticals, Inc, Cylene Pharmaceuticals, Genentech, Inc, Nereus Pharmaceuticals, Pfizer Inc, Roche Pharmaceuticals, and sanofi-aventis.
Available for CME/CE:
Physicians
Publish Date: Feb 5, 2010 Termination Date: Feb 5, 2011Nurses
Publish Date: Feb 5, 2010 Termination Date: Feb 5, 2010Pharmacists
Publish Date: Feb 5, 2010 Termination Date: Feb 5, 2011Estimated time for completion of this activity:
Target Audience
This activity is designed for oncologists and other clinicians who specialize in and care for patients with lung cancer.
Activity Goal
The goal of this CME/CE activity is to examine current and emerging strategies for treating and managing patients with lung cancer.
Learning Objective (s)
- Assess the presence of EGFR mutations in NSCLC patients to determine who may benefit from the EGFR inhibitor class of treatment options.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 7.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Each of the ten article reviews within this activity is worth 0.75 AMA PRA Category 1 Credits™.
CE Information: Nurses
Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Upon completion of this course, participants will be awarded 0.55 nursing contact hour(s).
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This article review is worth up to 0.75 contact hour (0.075 CEU). The ACPE Universal Program Number assigned to this activity is 0052-0000-10-238-H01-P.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that all those who have control of content comply with the Standards for Commercial Support. Faculty, planners, PIK editorial scientific team, reviewers, and medical writers are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed during the presentations.
Corey J. Langer, MD, FACP has received grant/research support from Bristol-Myers Squibb, Genentech, Inc, ImClone Systems, Lilly USA, LLC, OSI Pharmaceuticals, Inc. and Pfizer, Inc; is an advisor for Abraxis, Abbott, Amgen, AstraZeneca, Bayer/Onyx, Biodesix, Bristol-Myers Squibb, Caris Dx, Clarient Inc, Genentech Inc, ImClone Systems, Lilly USA, LLC, Morphotek, Novartis Pharmaceuticals, Pfizer, Inc, sanofi-aventis, and is on the speakers bureau of Genentech, Inc, ImClone-BMS, Lilly USA, LLC, and OSI Pharmaceuticals Inc.
Peer Reviewer has disclosed no relevant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no relevant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no relevant relationships to disclose.
Nicole M. Avena, PhD has disclosed no significant relationships.
Projects In Knowledge's staff members have no relevant relationships to disclose.
Planning Committee
Jeffrey D. Bradley, MD has disclosed no significant relationships.
Walter J. Curran, Jr., MD is a consultant for Eli Lilly and Company, GlaxoSmithKline, and ImClone Systems; and has ownership interest in ITA Partners.
Jessica S. Donington, MD has disclosed no significant relationships.
Roy S. Herbst, MD, PhD has received grant/research support from Amgen Inc, AstraZeneca, Bristol-Myers Squibb, Genentech, Inc, Geron Corporation, Novartis Pharmaceuticals, Oncothyreon, OSI Pharmaceuticals, Inc., and sanofi-aventis; is an advisor for Amgen Inc, AstraZeneca, Bristol-Myers Squibb, and Eli Lilly and Company; and is a consultant for Amgen Inc, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc, and SynDevRx.
Corey J. Langer, MD, FACP has received grant/research support from Bristol-Myers Squibb, Genentech, Inc, ImClone Systems, Lilly USA, LLC, OSI Pharmaceuticals, Inc. and Pfizer, Inc; is an advisor for Abbott Laboratories, Abraxis, Amgen Inc, AstraZeneca, Bayer/Onyx, Biodesix, Bristol-Myers Squibb, Caris Dx, Clarient, Inc, Genentech, Inc, ImClone Systems, Lilly USA, LLC, Morphotek, Novartis Pharmaceuticals, Pfizer, Inc, and sanofi-aventis; and is on the speakers bureau of Genentech, Inc, ImClone-BMS, Lilly USA, LLC, and OSI Pharmaceuticals Inc.
Vincent A. Miller, MD is a consultant for ArQule, Inc, Boehringer Ingelheim Pharmaceuticals, Inc, Cylene Pharmaceuticals, Genentech, Inc, Nereus Pharmaceuticals, Pfizer Inc, Roche Pharmaceuticals, and sanofi-aventis.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME/CE:
Physicians
Publish Date: Feb 5, 2010 Termination Date: Feb 5, 2011Nurses
Publish Date: Feb 5, 2010 Termination Date: Feb 5, 2010Pharmacists
Publish Date: Feb 5, 2010 Termination Date: Feb 5, 2011Estimated time for completion of this activity:
Target Audience
This activity is designed for oncologists and other clinicians who specialize in and care for patients with lung cancer.
Activity Goal
The goal of this CME/CE activity is to examine current and emerging strategies for treating and managing patients with lung cancer.
Learning Objective (s)
- Assess the presence of EGFR mutations in NSCLC patients to determine who may benefit from the EGFR inhibitor class of treatment options.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 7.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Each of the ten article reviews within this activity is worth 0.75 AMA PRA Category 1 Credits™.
CE Information: Nurses
Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Upon completion of this course, participants will be awarded 0.55 nursing contact hour(s).
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This article review is worth up to 0.75 contact hour (0.075 CEU). The ACPE Universal Program Number assigned to this activity is 0052-0000-10-238-H01-P.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that all those who have control of content comply with the Standards for Commercial Support. Faculty, planners, PIK editorial scientific team, reviewers, and medical writers are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed during the presentations.
Corey J. Langer, MD, FACP has received grant/research support from Bristol-Myers Squibb, Genentech, Inc, ImClone Systems, Lilly USA, LLC, OSI Pharmaceuticals, Inc. and Pfizer, Inc; is an advisor for Abraxis, Abbott, Amgen, AstraZeneca, Bayer/Onyx, Biodesix, Bristol-Myers Squibb, Caris Dx, Clarient Inc, Genentech Inc, ImClone Systems, Lilly USA, LLC, Morphotek, Novartis Pharmaceuticals, Pfizer, Inc, sanofi-aventis, and is on the speakers bureau of Genentech, Inc, ImClone-BMS, Lilly USA, LLC, and OSI Pharmaceuticals Inc.
Peer Reviewer has disclosed no relevant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no relevant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no relevant relationships to disclose.
Nicole M. Avena, PhD has disclosed no significant relationships.
Projects In Knowledge's staff members have no relevant relationships to disclose.
Planning Committee
Jeffrey D. Bradley, MD has disclosed no significant relationships.
Walter J. Curran, Jr., MD is a consultant for Eli Lilly and Company, GlaxoSmithKline, and ImClone Systems; and has ownership interest in ITA Partners.
Jessica S. Donington, MD has disclosed no significant relationships.
Roy S. Herbst, MD, PhD has received grant/research support from Amgen Inc, AstraZeneca, Bristol-Myers Squibb, Genentech, Inc, Geron Corporation, Novartis Pharmaceuticals, Oncothyreon, OSI Pharmaceuticals, Inc., and sanofi-aventis; is an advisor for Amgen Inc, AstraZeneca, Bristol-Myers Squibb, and Eli Lilly and Company; and is a consultant for Amgen Inc, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc, and SynDevRx.
Corey J. Langer, MD, FACP has received grant/research support from Bristol-Myers Squibb, Genentech, Inc, ImClone Systems, Lilly USA, LLC, OSI Pharmaceuticals, Inc. and Pfizer, Inc; is an advisor for Abbott Laboratories, Abraxis, Amgen Inc, AstraZeneca, Bayer/Onyx, Biodesix, Bristol-Myers Squibb, Caris Dx, Clarient, Inc, Genentech, Inc, ImClone Systems, Lilly USA, LLC, Morphotek, Novartis Pharmaceuticals, Pfizer, Inc, and sanofi-aventis; and is on the speakers bureau of Genentech, Inc, ImClone-BMS, Lilly USA, LLC, and OSI Pharmaceuticals Inc.
Vincent A. Miller, MD is a consultant for ArQule, Inc, Boehringer Ingelheim Pharmaceuticals, Inc, Cylene Pharmaceuticals, Genentech, Inc, Nereus Pharmaceuticals, Pfizer Inc, Roche Pharmaceuticals, and sanofi-aventis.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
|
